Our biotechnology consulting team brings strategic insights that help biotech companies build value and innovate with confidence.
How IntraBio's finance transformation fueled its global expansion
EY teams helped the biopharma company solve operational and financial challenges, helping it to focus on groundbreaking drug research.
Read more
Bayer's journey to becoming a preferred partner in clinical trials
The pharmaceutical company sought to improve site relationships and drive industry-leading practices.
CEO of Bayer AG on mission-first strategy
Strategy in Action, a CEO series by EY-Parthenon.
Learn more
Large language models are planting the seeds of the future
GenAI has helped organize the agronomic knowledge in a way that makes retrieval easy and accessible.
Discover key insights and unique perspectives on leading solutions, top biotech trends and industry-transforming issues.
Private Equity maintains strong interest in life sciences and healthcare
While deals in the life sciences space have been subdued over the last two to three years, money is still flowing into the healthcare space.
How AI in biopharma drives mission‑focused growth
AI in biopharma must go beyond operational efficiencies and cost savings become a strategic engine driving mission-centric growth and innovation.
Biotech VC Fundraising Down 2% in 2025, Early-Stage Companies Struggle
Biotech’s 2025 venture capital (VC) fundraising ended at $22.6 billion, down 2% from 2024 but still up 4% compared to the five-year average. Pretty encouraging.
EY Biotech Beyond Borders Report 2025: Texas Edition
Texas remains a compelling microcosm within the global biotech sector, which is marked by both uncertainty and promise.
Innovation is moving at an unprecedented speed. Are you staying with it?
Innovation has been the lifeblood of human productivity and value creation since the Industrial Revolution.
EY Biotech Beyond Borders Report 2025
As biopharma companies face a rapidly changing political landscape, we explore industry performance over the last year, including strategies that will position companies for long-term success.
Key steps for improving biopharma expansion into new markets
As biopharma companies look to new markets for growth, leaders need to tailor their expansion efforts to the nuances of each market.
New year, new hope for the biotech IPO market
Could we finally be witnessing the reopening of the biotech IPO window?
The BIOSECURE Act is now law. Are you ready?
After years of negotiations, the BIOSECURE Act was enacted into law in a version that reduces some of the anticipated disruption to the life sciences sector.
How can the life sciences industry go from fragmentation to creating a new fabric for innovation?
With the festive season on the horizon and the New Year also shaping up to be exciting, I’m not just looking forward to Santa and mince pies
Watch for us in market at key industry events or join the conversation via our webcast platform as EY thought leaders share new insights on the latest pharma trends.
Bio-IT World Expo
May 19-21, 2026
Boston, MA
Bio International Convention
June 22-25, 2026
San Diego, CA
Arda Ural, PhD EY Americas Life Sciences Sector Leader Ernst & Young LLP
Subscribe
From pharmaceutical M&A to capital optimization and more, we empower the pharmaceutical industry to drive innovation and growth.
How Bristol Myers Squibb overhauled working capital to fund its future
An EY-Parthenon team helped BMS establish a cash leadership office as part of an award-winning Treasury transformation. Learn more in this case study.
How Sigma, an Australian pharmaceutical company, transformed its supply chain
Discover how EY teams helped Sigma simplify and standardize to boost availability and cut inventory by 20%.
Accelerated access to novel cancer therapies at Moores Cancer Center
Moores Cancer Center accelerated activation of high-priority clinical trials by leveraging the EY Clinical Trial Fast Lane solution.
How tech and trust transformed a tax operating model
Global pharmaceutical player Boehringer Ingelheim is reimagining its tax operating model to boost quality and efficiency.
How a B2B company drove engagement by transforming its D2C platform
Merck Animal Health modernized its HomeAgain e-commerce site to offer customers a robust online experience that drives growth and expansion.
What going digital means for Takeda
Takeda Business Solutions fast-tracked its digitalization evolution through an innovative top-down and bottom-up journey.
How confident are you turning your vision into value?
Our deep experience helped a pharma company establish a global footprint.
Discover key insights and unique perspectives on leading solutions and top pharma industry trends.
How biopharmas can better integrate pre-commercial acquisitions
Acquiring pre-commercial assets is critical to fill biopharma development pipelines. The deals require a tailored integration approach.
How AI in biopharma drives mission-focused growth
How AI can form the foundation for an always-on biopharma deal radar
AI can help biopharma companies identify M&A targets to build up their R&D pipelines as they face a “patent cliff” for existing treatments.
EY Firepower Report: Life Sciences Dealmaking and M&A Growth Strategy
The EY 2026 Firepower M&A report finds life sciences companies recognizing the need to accelerate their dealmaking strategies to succeed in an increasingly competitive environment.
How to accelerate growth through commercial transformation in pharma
Facing intensifying pressure to drive stronger customer engagement, growth and efficiency, organizations in the industry must evolve.
How to make account-based selling work for pharma
Learn more about how EY teams can help you respond to changes that you can’t afford to ignore.
How to enhance traceability in the life sciences supply chain
As the need for enhanced traceability intensifies, modern solutions can help organizations drive patient safety and product integrity.
How next-generation CRM will reshape the life sciences commercial model
CRM must evolve from analogue maps to real-time GPS for pharma. Unlock deeper insights — transform your customer engagement now.
When and how to use GenAI in late-stage clinical development
GenAI and related tools can help improve the design of clinical trials and speed data gathering and regulatory reporting.
How to reach gold-standard operations in pharmaceutical manufacturing
The “golden batch” approach is poised to revolutionize pharma manufacturing by setting the standard for an ideal production run.
How biopharma can get the right mix of people and tech for launch success
Facing a challenging commercial environment, biopharma companies need to embrace an end-to-end, AI-driven strategy to succeed.
How AI can support decision-making in drug development portfolios
For the pharmaceutical industry, AI can be a powerful tool to drive better-informed asset portfolio decisions.
How real-time release (RTR) can transform pharmaceutical manufacturing
RTR has significant potential, but pharmaceutical manufacturers looking to adopt it must first meet several prerequisites.
Drive commercial success by effectively navigating loss of exclusivity
When patent expiration looms, strategic planning across functions can help pharma leaders increase value.
Why ‘AI by design’ is foundational to pharmaceutical manufacturing
To unlock the potential of AI, pharmaceutical manufacturers need a robust data foundation to drive success.
Life sciences dealmaking remains, with early-stage deals and China’s rise as a biotech hub continuing to take center stage
Life sciences is no longer just about molecules and microscopes. It’s about data, digital ecosystems and the ability to connect dots at lightning speed.
Why it’s time for pharma leaders to rethink quality
Pharmaceuticals manufacturers are facing increasing compliance regulations and challenges from global production.
ASEMBIA Summit
Las Vegas NV
April 26-30 2026
2026 PMSA Annual Conference
May 3-6, 2026
New Orleans, LA
We work closely with leading and emerging companies across the medical technology industry in key areas such as M&A and supply chain.
Explore key learnings from our strategic collaboration with leading pharma companies to develop targeted solutions.
The state of MedTech 2025
Hear from John Babitt, EY Global MedTech Leader, as he shares important highlights on the state of the industry.
How Medtronic’s optimized supply chain gets products to patients in need
A supply chain transformation enabled more personalized care for over 78 million patients.
Discover key insights and unique perspectives on leading solutions and top MedTech industry trends.
Pulse of the MedTech Industry Report 2025
Reigniting growth and expanding markets.
Investing in innovation: unlocking value in MedTech
For top performers, R&D investments fuel growth, increase investor confidence and unlock total shareholder return.
Pursuing the right deals now to deliver value into the future
Discussion with executive leaders from top Life Sciences companies.
How organizations can deliver medical device security the care it needs
Many smart medical devices in health care today are not designed with security in mind, exposing sensitive data to risk.
Watch for us in market at key industry events or join the conversation via our webcast platform as EY thought leaders share new insights on the latest MedTech industry trends.
The MedTech Conference
October 18-21, 2026
John Babitt EY Global MedTech Leader Ernst & Young LLP